Erin J. Walsh, PharmD, MS, RPh, told Pharmacy Times that VER-01 could change how clinicians use cannabis-derived medicines in chronic pain management. She framed VER-01 not as a replacement for existing treatments but as an additional, standardized option clinicians can consider when creating multimodal care plans.
Walsh emphasized three practical points. First, standardized pharmaceutical cannabinoids like VER-01 should meet the same clinical evidence standards required for any other prescription therapy. That means randomized trials, dose-finding studies, safety monitoring, and published outcomes that allow prescribers to compare risk–benefit profiles across drugs. Second, if regulators approve VER-01, clinicians could add it to combinations that already include analgesics, physical therapy, behavioral interventions, and interventional procedures. Third, ongoing research must identify which patient subgroups respond best and which combinations yield measurable improvement in pain scores, function, or opioid-sparing effects.
She warned against treating pharmaceutical cannabinoids and botanical cannabis as direct competitors. Instead, Walsh argued, they serve different clinical needs: an approved, standardized product offers consistent dosing, labeled safety information, and formal drug-interaction data; botanical products may retain value for patients who seek whole-plant formulations or alternative delivery methods. Validating the endocannabinoid system as a therapeutic target, Walsh said, would broaden options for clinicians and researchers working on pain and other indications.
Walsh repeated that no single therapy fits all patients. Chronic pain presents with diverse causes, durations, and comorbidities, so clinicians require a larger set of validated tools to tailor care. She called for head-to-head and adjunctive trials that measure concrete outcomes — for example, changes in validated pain scores, daily opioid dose reductions, functional status measures, and adverse event rates — instead of relying on anecdotal reports or informal patient feedback.
On safety and clinical integration, Walsh recommended several steps. Pharmacy teams should receive clear, product-specific guidance on dosing, titration schedules, contraindications, and interactions with opioids, benzodiazepines, and common cardiovascular drugs. Electronic health records and prescribing systems should flag documented drug interactions and provide monitoring checklists. Health systems should track patient-reported outcomes and adverse events so prescribers can quantify effectiveness and harms in their own populations.
Walsh also noted broader research implications. If VER-01 produces reproducible clinical effects and a defined safety profile, it could validate further investment in cannabinoid pharmacology and lead to next-generation molecules that target specific receptors or metabolic pathways in the endocannabinoid system. That would shift research from uncontrolled botanical studies toward regulated pharmaceutical development with defined endpoints.
She concluded that success should be measured at two levels: product performance and field-wide evidence improvement. A single approved drug matters less if it does not generate reliable data clinicians can use to compare therapies and to choose treatments for specific patient types. Conversely, programs that produce replicable trial data and published safety analyses will allow clinicians to integrate cannabinoid options with quantified expectations for benefit and harm.
Practical takeaway for clinicians: watch trial outcomes for VER-01, expect labeled dosing and interaction data if regulators approve it, and consider pharmaceutical cannabinoids as one additional tool for multimodal chronic pain care. Pharmacy and clinical teams should prepare protocols for safe prescribing and monitoring so that, when evidence becomes available, they can apply it to measurable patient outcomes.
